Table 1 Clinical characteristics of the study population
Characteristics | All (n = 54) | pCR (n = 10) | Non-pCR (n = 36) | P |
|---|---|---|---|---|
| Â | n (%) | n (%) | n (%) | Â |
Age | Â | Â | Â | 0.67 |
 Mean(range) | 63 (48,75) | 63 (55,70) | 62 (48,75) |  |
 ≤ 60 | 15 (27.8) | 2 (20.0) | 12 (33.3) |  |
 > 60 | 39 (72.2) | 8 (80.0) | 24 (66.7) |  |
Sex | Â | Â | Â | 0.50 |
 Male | 49 (90.7) | 10 (100.0) | 31 (86.1) |  |
 Female | 5 (9.3) | 0 (0.0) | 5 (13.9) |  |
Tumor location | Â | Â | Â | 0.28 |
 Proximal | 8 (14.8) | 2 (20.0) | 5 (13.8) |  |
 Middle | 16 (29.6) | 1 (10.0) | 13 (36.2) |  |
 Distal | 30 (55.5) | 7 (70.0) | 18 (50.0) |  |
Length, cm | Â | Â | Â | 0.47 |
 Mean (range) | 6 (3,10) | 6 (4,9) | 6 (3,10) |  |
 ≤ 6 cm | 38 (70.4) | 6 (60.0) | 28 (77.8) |  |
 > 6 cm | 16 (29.6) | 4 (40.0) | 8 (22.2) |  |
Clinical T stage | Â | Â | Â | 0.39 |
 T1-2 | 2 (3.7) | 1 (10.0) | 1 (2.8) |  |
 T3-4 | 52 (96.3) | 9 (90.0) | 35 (97.2) |  |
Clinical N stage | Â | Â | Â | 0.61 |
 N negative | 3 (48.1) | 1 (60.0) | 2 (50.0) |  |
 N positive | 51 (51.9) | 9 (40.0) | 34 (50.0) |  |
Clinical stage | Â | Â | Â | 0.91 |
 II | 2 (3.7) | 1 (10.0) | 1 (2.8) |  |
 III | 52 (96.3) | 9 (90.0) | 35 (97.2) |  |
Chemotherapy | Â | Â | Â | Â |
 Weekly | 32 (59.3) | 4 (40.0) | 21 (58.3) | 0.50 |
 3-weekly | 22 (40.7) | 6 (60.0) | 15 (41.7) |  |